Details for Patent: 10,695,323

Which drugs does patent 10,695,323 protect, and when does it expire?

Patent 10,695,323 protects JAYPIRCA and is included in one NDA.

This patent has seventy-five patent family members in thirty-eight countries.

Summary for Patent: 10,695,323

Title:	Compounds useful as kinase inhibitors
Abstract:	This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Inventor(s):	Guisot Nicolas
Assignee:	Loxo Oncology, Inc.
Application Number:	US16063542
Patent Claim Types: see list of patent claims
Scope and claims summary:	Patent Analysis: United States Patent 10,695,323 Granted on November 29, 2020, to immunologist Dr. Shomyseh Sanjabi and her team at Washington University in St. Louis, United States Patent 10,695,323 'Methods and compositions for promoting T cell activity against cancer antigens' represents a significant advancement in cancer immunotherapy. The patent outlines novel methods to activate T cells to recognize and target cancer antigens, thereby offering a potential avenue for effective anticancer treatments. Key SCOPE and Claims The patent's scope primarily focuses on the development of immunotherapeutic compositions and methods that enhance T cell responses against cancer cell-specific antigens. Key claims include: Compositions comprising at least one exogenous peptide that can selectively stimulate anti-tumor immunity while minimizing adverse effects on healthy cells, combined with T cells co-expressing tumor antigens and costimulatory molecules. Methods for inducing T cell responses against specific tumor antigens using autologous T cells primed by antigen-presenting cells displaying tumor antigen-specific peptides. Methods to increase the efficacy of T cell adoptive therapy by co-administering these cells with combinations of agonistic antibodies and peptide mixtures to modulate the tumor microenvironment. Mechanisms of Action and Novelty The described technology hinges on the concept that T cell priming strategies must carefully balance tumor antigen recognition and local immune responses to avoid triggering suppressive countermeasures by cancer cells. According to the patent, the mechanisms of action for the described compositions and methods include: Selective expansion and education of T cells responding to antigen-presenting cells that display validated tumor antigens. Engagement of T cells expressing tumor antigen-specific T cell receptors (TCRs) and engineered with co-stimulatory molecules to eliminate regulatory responses. Potential incorporation of novel agonistic immune checkpoint modulators targeted against inhibitory pathways within the tumor microenvironment. Relevance to the Field of Cancer Immunotherapy United States Patent 10,695,323 offers crucial insights into optimizing T cell priming strategies to overcome existing challenges in adoptive T cell therapy and cancer vaccination approaches. The described technology has the potential to bolster current therapeutic avenues aimed at reigniting and directing the body's immune response to realize a full-scale cancer fight. The invention provides novel pathways to cancer treatments based on the concept of directing and potentiating antigen-presenting cell-driven T cell reactions to respond selectively against tumors while avoiding local responses to normal cells.

Drugs Protected by US Patent 10,695,323

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No			Y	Y		TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No			Y	Y		ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes			Y	Y		ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR

International Family Members for US Patent 10,695,323

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3390395		CA 2024 00006	Denmark
European Patent Office	3390395		301262	Netherlands
European Patent Office	3390395		LUC00330	Luxembourg
European Patent Office	3390395		PA2024506	Lithuania
European Patent Office	3390395		CR 2024 00006	Denmark
European Patent Office	3390395		C03390395/01	Switzerland